Vytrus Biotech S.A. | Small-cap | Healthcare
€5.60
1.82%
| Vytrus Biotech S.A Stock Comparison:
Vytrus Biotech S.A vs Pharma Mar S.AVytrus Biotech S.A vs Atrys Health S.AVytrus Biotech S.A vs Biotechnology AssetsVytrus Biotech S.A vs Oryzon Genomics S.AVytrus Biotech S.A vs Grifols, S.AVytrus Biotech S.A vs IBEX 35 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 11.1M
Total Liabilities 3.8M
Shareholders Equity 7.3M
Debt to Equity 0.53

Cash Flow Metrics

Revenue & Profitability Trend

Vytrus Biotech S.A Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i5.0M3.7M3.7M2.8M1.7M
Cost of Goods Sold i-453.5K-611.0K-448.3K-449.6K-355.7K
Gross Profit i5.5M4.3M4.1M3.3M2.1M
Gross Margin % i109.0%116.4%112.2%116.0%120.9%
Operating Expenses
Research & Development i----149.0K
Selling, General & Administrative i--1.1M872.8K212.0K
Other Operating Expenses i1.4M1.2M1.1M881.4K233.0K
Total Operating Expenses i1.4M1.2M2.2M1.8M594.0K
Operating Income i1.0M454.3K644.7K429.9K166.9K
Operating Margin % i19.9%12.2%17.5%15.3%9.8%
Non-Operating Items
Interest Income i-----
Interest Expense i----115.8K
Other Non-Operating Income-----
Pre-tax Income i901.7K308.3K452.8K309.2K91.6K
Income Tax i-119.3K-236.6K-152.5K-140.9K-125.3K
Effective Tax Rate % i-13.2%-76.7%-33.7%-45.6%-136.8%
Net Income i1.0M544.9K605.3K450.0K216.9K
Net Margin % i20.2%14.6%16.4%16.0%12.7%
Key Metrics
EBITDA i1.8M1.2M1.3M1.0M560.6K
EPS (Basic) i-€0.08€0.09€0.06€0.03
EPS (Diluted) i-€0.08€0.09€0.06€0.03
Basic Shares Outstanding i-6735393684436772589517258951
Diluted Shares Outstanding i-6735393684436772589517258951

Income Statement Trend

Vytrus Biotech S.A Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i2.5M1.1M724.6K1.3M1.1M
Short-term Investments i600600-522742
Accounts Receivable i617.8K550.3K436.3K211.1K167.7K
Inventory i519.3K551.0K411.3K260.4K207.7K
Other Current Assets--100-0
Total Current Assets i3.8M2.5M1.7M1.8M1.5M
Non-Current Assets
Property, Plant & Equipment i331.2K326.1K313.7K202.5K1.0M
Goodwill i4.1M3.6M3.2M2.8M2.5M
Intangible Assets i4.1M3.6M3.2M2.8M2.5M
Long-term Investments-----
Other Non-Current Assets-0--0
Total Non-Current Assets i7.3M6.9M6.3M5.4M4.7M
Total Assets i11.1M9.3M8.0M7.2M6.2M
Liabilities
Current Liabilities
Accounts Payable i97.8K37.8K171.6K163.9K78.9K
Short-term Debt i485.2K485.5K736.8K348.8K406.2K
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i1.3M995.8K1.3M806.1K643.4K
Non-Current Liabilities
Long-term Debt i2.0M2.4M1.3M1.5M1.5M
Deferred Tax Liabilities i594.3K659.9K693.3K588.3K466.9K
Other Non-Current Liabilities-----
Total Non-Current Liabilities i2.6M3.0M2.0M2.1M2.0M
Total Liabilities i3.8M4.0M3.3M2.9M2.6M
Equity
Common Stock i76.4K71.2K71.2K71.2K69.7K
Retained Earnings i1.0M544.9K605.3K450.0K100.3K
Treasury Stock i281.6K895.2K587.6K233.7K34.3K
Other Equity-----
Total Shareholders Equity i7.3M5.3M4.8M4.3M3.6M
Key Metrics
Total Debt i2.5M2.9M2.0M1.9M1.9M
Working Capital i2.5M1.5M414.4K1.0M895.0K

Balance Sheet Composition

Vytrus Biotech S.A Cash Flow Statement From 2021 to 2024

Metric2024202320222021
Operating Activities
Net Income i901.7K308.3K452.8K309.2K
Depreciation & Amortization i----
Stock-Based Compensation i----
Working Capital Changes i32.4K-252.2K-5.3M-95.3K
Operating Cash Flow i962.8K145.8K-4.7M-399.9K
Investing Activities
Capital Expenditures i-101.0K-141.5K-420.3K-220.6K
Acquisitions i-3.0K---
Investment Purchases i-1.0K-15.6K-32.3K-31.0K
Investment Sales i4.4K539--
Investing Cash Flow i-100.6K-156.6K-452.6K-251.5K
Financing Activities
Share Repurchases i-138.0K-421.1K-464.6K-199.4K
Dividends Paid i----
Debt Issuance i200.0K1.6M381.5K265.5K
Debt Repayment i-609.2K-683.3K-347.1K-271.5K
Financing Cash Flow i783.1K657.0K-258.2K45.0K
Free Cash Flow i640.2K-261.8K-268.6K176.1K
Net Change in Cash i1.6M646.2K-5.4M-606.4K

Cash Flow Trend

Vytrus Biotech S.A Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 39.29
Forward P/E 16.14
Price to Book 5.68
Price to Sales 6.79

Profitability Ratios

Profit Margin 16.76%
Operating Margin 15.45%
Return on Equity 16.23%
Return on Assets 6.02%

Financial Health

Current Ratio 3.03
Debt to Equity 24.31
Beta 0.04

Per Share Data

EPS (TTM) €0.14
Book Value per Share €0.97
Revenue per Share €0.81

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
vyt41.4M39.295.6816.23%16.76%24.31
Pharma Mar S.A 1.4B33.616.8321.94%22.20%25.51
Atrys Health S.A 214.1M-6.690.85-11.73%-14.57%100.85
Biotechnology Assets 24.1M10.773.56-44.40%-98.39%31.56
Oryzon Genomics S.A 203.9M-44.561.96-4.20%-58.55%15.22
Grifols, S.A 7.8B29.191.694.99%4.00%126.87

Financial data is updated regularly. All figures are in the company's reporting currency.